← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Lung Therapeutics, Inc.
Tyler, TX
$1,009,557
Total funding
4
Grants
Funding over time
peak $300.2K · FY2018–23$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,009,557 · 4
By mechanism
R43$784,560 · 3
R41$224,997 · 1
Investigators at Lung Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
DEVELOPMENT AND TESTING OF SUBCUTANEOUS CSD PEPTIDE FORMULATIONS FOR CHRONIC KIDNEY DISEASE$300,228
R43 · FY2020 · DK
The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS)$259,332
R43 · FY2023 · HL
Caveolin-1 replacement therapy for the treatment of Idiopathic Pulmonary Fibrosis$225,000
R43 · FY2019 · HL
Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD)$224,997
R41 · FY2018 · HL